Anavex Life Sciences Corp (AVXL)

[Investor2014]

Well if due to titration, tolerability and non linear multifactorial relationships we don't see therapeutic response clearly divided between the two dose arms as per trial design, then as before subgroup analysis ensues to eek out those patients that improved and why regardless of in which dose assignment arm responders may be found.

For that reason as per all the slides I referenced, concentration is the target of interest to analysis, not dose. So for a follow on P3 PM trial, if required as I believe, there could be a placebo arm a single dose titration arm that will be likely to show stat sig classic results over placebo.